Small dose of daunorubicin induced acute myeloid leukemia observed

Objective:To investigate the small dose of daunorubicin(DNR) induced acute myeloid leukemia(AML) remission of clinical efficacy.Methods:80 cases of elderly AML patients were randomly divided into treatment group(40 cases) and control group(40 cases),two groups of patients were treated with DA chemotherapy,patients treated with smaller doses of daunorubicin 30 mg/(m2·d),control group of patients with standard doses of daunorubicin 45 mg/(m2·d),followed 2 courses of treatment were compared the clinical efficacy and Ⅲ degrees of bone marrow suppression,infections,gastrointestinal reactions and other adverse drug reactions.Results:The patients with complete remission in 16 cases,remission rate of 40% in the control group were complete remission in 18 cases,45% response rate,complete remission rate between the two groups were not significantly different(P0.05);treatment of poor patients reaction in 11 cases,accounting for 28% in the control group were adverse events in 18 cases,45% in the control group rate of adverse events was significantly higher than the treatment group,two groups were statistically significant differences(P0.05).Conclusion:The low dose of daunorubicin induced elderly AML,satisfactory outcome,adverse drug reaction is little worthy to be popularized.